<DOC>
	<DOCNO>NCT01176175</DOCNO>
	<brief_summary>Phase : I pharmacokinetic - pharmacodynamic ( PK-PD ) study . Main objective : To establish minimum effective dose progesterone microspheres suspension , administer weekly intramuscular injection , able induce transformation proliferative endometrium secretory endometrium . Study design : Randomized , control , open-label , parallel , dose-response clinical trial . Sites : 1 Subjects : 48 postmenopausal woman .</brief_summary>
	<brief_title>Progesterone Microspheres Pharmacokinetic - Pharmacodynamic ( PK-PD ) Study</brief_title>
	<detailed_description>Sites : 1 Phase : 1 Main objective : To establish minimum effective dose progesterone microspheres suspension , administer weekly intramuscular injection , able induce transformation proliferative endometrium secretory endometrium . Secondary objective : - To determine compare steady-state pharmacokinetic profile investigational product . - To evaluate safety profile investigational product study subject . - To evaluate local tolerability investigational product study subject . Study design : Randomized , control , open-label , parallel , dose-response clinical trial . Investigational product : - Progesterone microspheres intramuscular injectable suspension 50 mg - Progesterone microspheres intramuscular injectable suspension 100 mg - Progesterone microspheres intramuscular injectable suspension 200 mg - Progesterone microspheres intramuscular injectable suspension 300 mg Study subject : 48 healthy postmenopausal woman , 45 - 60 year . Brief description : After write informed consent , 48 eligible woman receive pretreatment oral estradiol valerate , , 14 day later , adequate endometrial thickness evaluate ultrasound randomize study treatment ( one IM injection 7 day , total 7 dos ) . 10 day first progesterone dose , endometrial biopsy obtain . Blood sample obtain pharmacokinetic study .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Female 45 60 year old Able read write Postmenopausal Body Mass Index equal 34.99 kg/m2 Healthy Normal uterus Time availability Hypersensitivity progesterone relate compound Hypersensitivity estrogens Hysterectomy History present hormonedependent tumor History present uterine cervix dysplasia Abnormal clinicallysignificant laboratory test result Family history breast cancer History thromboembolic disease Noncontrolled hypertension History stroke History cardiac valve surgery Renal failure Hepatic failure Noncontrolled diabetes Severe gastrointestinal disease History serious neurologic disease Reduced mobility Anemia Previous concomitant hormonal therapy Previous concomitant therapy inhibitor inductor cytochrome</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Progesterone</keyword>
	<keyword>Microspheres</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>Luteal phase support</keyword>
</DOC>